Systemic and local predictors of medication-related osteonecrosis of the jaw in patients receiving antiresorptive therapy: The Shizuoka Kokuho Database study
Bone · 2026-10 · 211 · 117993
DOI: 10.1016/j.bone.2026.117993 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bone, 2026-10. Verfasst von Kanako Tsuboi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Public Health, Shizuoka Graduate University of Public Health, Shizuoka, Japan; Department of Oral and Maxillofacial Surgery, Haiba…. Hauptthemen laut MEDLINE: Databases, Factual, Bisphosphonate-Associated Osteonecrosis of the Jaw, Bone Density Conservation Agents. Die Arbeit nennt 37 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious adverse effect of antiresorptive therapy. We aimed to identify dose-specific predictors for MRONJ risk stratification. METHODS We conducted a retrospective cohort study using the Shizuoka Kokuho Database, an insurance claims database. Patients ≥40 years with osteoporosis or cancer who initiated bisphosphonate or denosumab between April 2015 and September 2022 were stratified into low- and high-dose groups. The outcome was MRONJ. Candidate predictors were defined using the information available before initiation of antiresorptive therapy, including demographics, comorbidities, medications, and dental care in the preceding month (no visit, maintenance, or oral risk treatment). We estimated the subdistribution hazard ratio (SHR) and its 95% confidence interval (CI) using Fine-Gray competing risk models with all-cause mortality as the competing risk. RESULTS Among 104,349 patients (low-dose, 99,572; high-dose, 4777), MRONJ occurred in 148 (46.7/100,000 person-years) and 105 (2116/100,000 person-years), respectively. Oral risk treatment within 1 month before therapy initiation was associated with MRONJ in both groups (low-dose: SHR 2.99 [95% CI 1.47-6.07]); high-dose: 4.28 [2.47-7.42]). Additional predictors were anemia (1.89 [1.31-2.71]) and oral corticosteroid use (2.27 [1.43-3.62]) in the low-dose group. CONCLUSION Predictors of MRONJ differed between antiresorptive dose groups. Oral risk treatment immediately before therapy initiation was consistently associated with higher MRONJ occurrence, suggesting that oral risk conditions near initiation may be important for risk stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School of Public Health, Shizuoka Graduate University of Public Health, Shizuoka, Japan; Department of Oral and Maxillofacial Surgery, Haibara General Hospital, Shizuoka, Japan.
- Graduate School of Public Health, Shizuoka Graduate University of Public Health, Shizuoka, Japan.
- Department of Oral and Maxillofacial Surgery, Haibara General Hospital, Shizuoka, Japan.
- Graduate School of Public Health, Shizuoka Graduate University of Public Health, Shizuoka, Japan. Electronic address: sato.yoko@s-sph.ac.jp.
Zitieren
APA
Tsuboi, K., Kinoshita, K., Matsushita, F., & Sato, Y. (2026). Systemic and local predictors of medication-related osteonecrosis of the jaw in patients receiving antiresorptive therapy: The Shizuoka Kokuho Database study. Bone, 211, 117993. https://doi.org/10.1016/j.bone.2026.117993
Vancouver
Tsuboi K, Kinoshita K, Matsushita F, Sato Y. Systemic and local predictors of medication-related osteonecrosis of the jaw in patients receiving antiresorptive therapy: The Shizuoka Kokuho Database study. Bone. 2026;211:117993. doi:10.1016/j.bone.2026.117993
BibTeX
@article{Tsuboi2026,
author = {Tsuboi, Kanako and Kinoshita, Kazuo and Matsushita, Fumihiko and Sato, Yoko},
title = {Systemic and local predictors of medication-related osteonecrosis of the jaw in patients receiving antiresorptive therapy: The Shizuoka Kokuho Database study},
journal = {Bone},
year = {2026},
volume = {211},
pages = {117993},
doi = {10.1016/j.bone.2026.117993}
}
EUVIMED